Kosidina (Ethinylestradiol, Gestodene)

Ethynylestradiol provides estrogenic activity while gestodene supplies progestogenic activity. Together they suppress the release of luteinizing hormone and follicle‑stimulating hormone, preventing ovulation, and they also modify cervical mucus and endometrial tissue to reduce the chance of fertilization and implantation.

The dosing regimen for Kosidina is determined by the prescribing healthcare professional. Typically, it is taken as a daily oral tablet according to a specific cycle, but the exact schedule and any missed‑dose instructions must be provided by the prescriber.

Kosidina is intended for use only when pregnancy is not present. If a woman becomes pregnant while taking the product, she should discontinue it and consult her physician. Use during breastfeeding should be discussed with a healthcare provider, as hormonal contraceptives may affect milk production.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kosidina contains ethynylestradiol and gestodene, a low‑dose estrogen‑progestin combination that offers effective pregnancy prevention with a favorable bleeding profile. Compared with some alternatives that use higher estrogen doses or different progestins, Kosidina may have a lower risk of estrogen‑related side effects while maintaining contraceptive efficacy.

Kosidina tablets should be stored at ambient temperature, below 25 °C, in their original packaging. Keep them away from moisture, direct sunlight and excessive heat to maintain product stability throughout its shelf life.

Kosidina is taken orally, usually once daily at the same time each day. The tablet is swallowed whole with water and should be started according to the prescriber’s instructions, often on the first day of the menstrual period.

Serious risks include blood clots such as deep‑vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Women with a history of thromboembolic disease, smoking, hypertension, or certain genetic clotting disorders should be evaluated carefully before use.

Kosidina is contraindicated in women who are pregnant, have known or suspected breast cancer, active liver disease, uncontrolled hypertension, a history of thromboembolic events, or who are smokers over 35 years of age. It should also be avoided in individuals with known hypersensitivity to any component of the tablet.